CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will be hosting a virtual RNAi Roundtable to discuss ALN-TTR for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) on Thursday, July 22, 2010 at 2:00 p.m. ET.
